KRAS and non-small cell lung carcinoma: In this multivariate model, the presence of plasma KRAS G12/G13 mutations, was found to be a strong independent predictor of adverse prognosis for both PFS ((HR) = 3.12, (95% CI) = 1.72–5.67, p < 0.001) and OS ((HR) = 2.53, (95% CI) = 1.40–4.56, p = 0.002) in NSCLC patients.